APA (7th ed.) Citation

Dunn, B., Stein, P., & Cavazzoni, P. (2021). Approval of Aducanumab for Alzheimer Disease-The FDA's Perspective. JAMA internal medicine, 181(10), 1276. https://doi.org/10.1001/jamainternmed.2021.4607

Chicago Style (17th ed.) Citation

Dunn, Billy, Peter Stein, and Patrizia Cavazzoni. "Approval of Aducanumab for Alzheimer Disease-The FDA's Perspective." JAMA Internal Medicine 181, no. 10 (2021): 1276. https://doi.org/10.1001/jamainternmed.2021.4607.

MLA (9th ed.) Citation

Dunn, Billy, et al. "Approval of Aducanumab for Alzheimer Disease-The FDA's Perspective." JAMA Internal Medicine, vol. 181, no. 10, 2021, p. 1276, https://doi.org/10.1001/jamainternmed.2021.4607.